The human immunodeficiency virus, type 1 (HIV-1)2 envelope (Env) glycoprotein mediates virus entry and is a major target of broadly neutralizing antibodies (bnAbs) developed during the course of infection in a subset of individuals (1). This evidence concerns the gene ERVW-1 and infection.